RecruitingNot ApplicableNCT07255937

PMCF Study of Debridement Pad

Post Market Clinical Follow up Study to Confirm the Ongoing Safety and Performance of a Debridement Pad in Superficial, Chronic and Acute Wounds

Sponsor

Advanced Medical Solutions Ltd.

Enrollment

184 participants

Start Date

Nov 20, 2025

Study Type

INTERVENTIONAL

Conditions

Venous Leg Ulcer Diabetic Ulcers Arterial Leg Ulcer

Summary

The design of the study is a clinical trial of Debridement Pad in subjects with superficial, chronic and acute wounds consisting of Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic or surgical wounds and burns and scalds. The performance data from this study will support clinically meaningful rates of successful improvement in wound bed condition immediately after treatment.

Eligibility

Min Age: 18 Years

Inclusion Criteria7

Males or females aged 18 years or above.
Patients who can understand and give informed consent to take part in the study.
Have one or more of the following wounds: Diabetic ulcers, Arterial and Venous Leg ulcers, Pressure ulcers, Postoperative wounds healing by secondary intention, traumatic and surgical wounds, and burns and scalds
Wounds that require debridement due to the presence of slough debris/fibrous tissue ,hyperkeratotic debris and dried exudate on the peri wound skin.
Wounds with both serous crusts and healthy tissue.
Minimum of 30% of the wound covered by debris, necrosis or slough.
Wound Size \> 4cm2

Exclusion Criteria7

Patients who are known to be non-compliant with medical treatment
Patients who are known to be sensitive to any of the device components such as polyester.
Subject has any significant or unstable medical or psychiatric condition that, in the opinion of the Investigator, would interfere with their ability to participate in the study.
Subject is currently enrolled in another clinical study, or has completed a clinical study less than 30 days prior to enrolment.
Symptoms \& signs of systemic and / or spreading wound infection (including erythema and fever).
Severe pain (level 7 or higher on a 0-10 VAS or hyperaesthesia in the wound area).
Subjects who in the view of the investigator might not be suitable for inclusion in the study

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.